BioSpace News Archive

Drug Development

Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent.

June 3, 2019
·
11 min read
Drug Development

NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation

June 3, 2019
·
3 min read
Business

William Shatner Announced as SoClean Spokesperson and Ambassador

Actor and Comedian Will Help the Company Behind the Groundbreaking CPAP Cleaner Advance Its Mission to Improve Lives of Sleep Apnea Sufferers Worldwide

June 3, 2019
·
2 min read
Business

Cirius Therapeutics Adds to Leadership Team

Cirius Therapeutics announced that Andrew Knudten, M.B.A., will join the company as chief technical officer and will be responsible for advancing the company’s manufacturing and supply chain operations.

June 3, 2019
·
2 min read
Business

Thermo Fisher Scientific Announces Collaboration with Newomics to Advance Disease Biomarker Validation

Thermo Fisher and Newomics to optimize performance of high-throughput analytical workflows

June 3, 2019
·
3 min read
Business

New-Generation Benchtop Mass Spectrometer Advances Quantitative Proteomics and Translational Research

Thermo Scientific Orbitrap Exploris 480 mass spectrometer designed for high-throughput biopharmaceutical and academic research laboratories

June 3, 2019
·
5 min read
Business

Waud Capital Appoints Ken Collins as Principal, Healthcare Services

Waud Capital Partners, a leading growth-oriented middle-market private equity firm, announced the appointment of Ken Collins as Principal, Healthcare Services, effective immediately.

June 3, 2019
·
2 min read
Pharm Country

Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles

Company Presentation Scheduled for Wednesday June 5, 2019 at 11:40 a.m. Pacific Time.

June 3, 2019
·
3 min read
Business

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Carisma Therapeutics Inc. announced Robert Petit, Ph.D., as its Chief Scientific Officer.

June 3, 2019
·
2 min read
Policy

Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Reviva Pharmaceuticals, Inc. announced that it has successfully completed a pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis.

June 3, 2019
·
4 min read